PureHealth Posts $550M Profit, Eyes Global Dominance with AI & Deals

ABU DHABI, UAE – February 09, 2026 – PureHealth Holding PJSC has solidified its position as a formidable force in global healthcare, announcing a net profit of USD 550 million for the 2025 fiscal year, a robust 17.7% increase year-on-year. The Middle East's largest healthcare group reported revenues of USD 7.4 billion and has proposed a USD 163 million dividend for shareholders, signaling strong confidence in its financial health and ambitious growth strategy.

The impressive financial results are the outcome of a dual-pronged strategy that combines aggressive international expansion with a deep, systemic investment in artificial intelligence and digital health infrastructure, reshaping its operations from Abu Dhabi to the United States.

A Global Footprint Forged Through Strategic Acquisitions

PureHealth's transformation into a global entity has accelerated significantly, with total assets now reaching USD 15.6 billion and approximately 50% of that base residing outside the UAE. This shift is a direct result of a calculated and aggressive acquisition strategy.

The most recent major move was the completion of a EUR 800 million acquisition for a 60% stake in Hellenic Healthcare Group (HHG), the leading private healthcare provider in Greece and Cyprus. The deal, which brings 11 hospitals and 23 diagnostic centers into the fold, already made a tangible impact, contributing USD 202 million in revenue and USD 41 million to Group EBITDA in the fourth quarter of 2025 alone.

This follows the landmark USD 1.2 billion acquisition of Circle Health Group, the UK's largest independent hospital operator, in 2024. PureHealth has not only focused on integration but also on expansion, driving a solid financial turnaround at Circle Health and pursuing bolt-on acquisitions like Fairfield Independent Hospital to strengthen its UK clinical footprint. This international momentum is a core tenet of the group's vision.

Farhan Malik, Founder and Managing Director of PureHealth, emphasized this global focus in the company's announcement. "With c.50% of assets now outside the UAE, PureHealth is a truly international business with diversified revenues across markets and currencies," he stated. "This performance enables us to reward shareholders with a dividend of USD 163 million while continuing to invest in the next phase of PureHealth's local and global expansion."

Betting on Bytes: AI and Digital Health at the Core

Beyond geographic expansion, PureHealth is making a profound bet on technology to redefine healthcare delivery. The company is embedding AI and digital solutions across its vast network, aiming to create a distinct competitive advantage.

A cornerstone of this initiative is PureLab, the UAE's largest and most advanced AI-powered standalone diagnostic laboratory. The 70,000-square-foot facility leverages robotics and AI to process over 30 million samples annually, utilizing AI-powered digital pathology to provide rapid, precise analysis of disease markers. It serves as a national hub, connecting oncology centers for real-time remote consultations.

On the patient-facing side, PureHealth launched nationwide virtual mental health services through its AI-enabled app, Pura. The app serves as a comprehensive digital health partner, integrating teleconsultations, medication management, and wellness tracking. Internally, the company is also rolling out AI tools to support clinicians with faster, data-driven decision-making, aiming to enhance accuracy and efficiency.

Group CEO Shaista Asif commented on the strategic importance of this technological push: "The scale of digital solutions and AI deployment we are implementing is creating a distinctive platform that sets us apart from major international providers, positioning us well ahead for the new era of AI-powered healthcare."

Strong Financials Fuel Shareholder Returns and Future Growth

The company’s financial performance underpins its dual ambitions of global growth and technological leadership. The 16.1% year-on-year increase in EBITDA to USD 1.3 billion was driven by efficiency gains and the successful integration of new assets like HHG. This financial strength provides the foundation for the proposed USD 163 million dividend, which represents a payout of approximately 30% of the net profit.

This move to reward investors builds on a pattern, following a USD 93.4 million dividend distribution after its 2023 IPO on the Abu Dhabi Stock Exchange. It reflects a disciplined capital allocation strategy that balances immediate shareholder value with long-term investment.

H.E. Kamal Al Maazmi, Chairman of PureHealth, noted, "The proposed dividend policy reflects the Board's confidence in the financial strength PureHealth has built and our commitment to delivering sustainable shareholder value while maintaining the flexibility to invest in long-term growth."

The group's integrated 'Care' (healthcare) and 'Cover' (insurance) model proved resilient. The insurance vertical saw revenues climb 13.5% to USD 2.1 billion, with memberships growing to 3.4 million.

Fortifying the Home Base While Expanding Abroad

While its international moves capture headlines, PureHealth continues to fortify its dominant position within the UAE. The group has been expanding its domestic capacity and capabilities, with outpatient and inpatient volumes increasing by 15% and 14%, respectively, in 2025. Hospital occupancy across its UAE network grew to a healthy 74%.

Key strategic initiatives in the UAE include the introduction of the Pura Longevity Clinic, focusing on preventive and precision medicine, and a landmark partnership between its SEHA network and Cincinnati Children's, the top-ranked children's hospital in the USA, to elevate paediatric care. SEHA also deployed advanced CyberKnife technology for non-invasive cancer treatment, enhancing its specialized oncology services.

Looking ahead, PureHealth plans to continue its aggressive growth trajectory. The company aims to further scale its global network, deepen its clinical specializations, and accelerate the deployment of its AI and digital capabilities. With a clear ambition for international markets to eventually contribute 50% of group revenue, PureHealth is charting a course to become not just a regional leader, but a defining player on the world's healthcare stage.